JP2003523988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003523988A5 JP2003523988A5 JP2001561714A JP2001561714A JP2003523988A5 JP 2003523988 A5 JP2003523988 A5 JP 2003523988A5 JP 2001561714 A JP2001561714 A JP 2001561714A JP 2001561714 A JP2001561714 A JP 2001561714A JP 2003523988 A5 JP2003523988 A5 JP 2003523988A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- alkyl
- chloro
- oxy
- benzonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 description 54
- 150000001875 compounds Chemical class 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- 125000003545 alkoxy group Chemical group 0.000 description 34
- 150000003839 salts Chemical class 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 26
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 229910052799 carbon Inorganic materials 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 125000005842 heteroatom Chemical group 0.000 description 17
- 229910052757 nitrogen Inorganic materials 0.000 description 17
- 229910052717 sulfur Inorganic materials 0.000 description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 13
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- -1 alkoxy radical Chemical class 0.000 description 12
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 8
- 125000000623 heterocyclic group Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 7
- 108010029485 Protein Isoforms Proteins 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 4
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 4
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229940111134 coxibs Drugs 0.000 description 4
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 235000019341 magnesium sulphate Nutrition 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- SMUWKRUWTDAYKS-UHFFFAOYSA-N 4-chloro-2-hydroxybenzonitrile Chemical compound OC1=CC(Cl)=CC=C1C#N SMUWKRUWTDAYKS-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- DMHJCNXEGYOJMG-LLVKDONJSA-N (3r)-3-(2,5-dichlorophenoxy)-3-(1,2-oxazol-3-yl)propan-1-amine Chemical compound O([C@H](CCN)C1=NOC=C1)C1=CC(Cl)=CC=C1Cl DMHJCNXEGYOJMG-LLVKDONJSA-N 0.000 description 1
- LVALLBOPNWLWKW-SNVBAGLBSA-N (3r)-3-(2,5-dichlorophenoxy)-3-(1,2-oxazol-5-yl)propan-1-amine Chemical compound O([C@H](CCN)C=1ON=CC=1)C1=CC(Cl)=CC=C1Cl LVALLBOPNWLWKW-SNVBAGLBSA-N 0.000 description 1
- RIVMWJNNCKIJOQ-LJQANCHMSA-N (3r)-3-(2,5-dichlorophenoxy)-3-phenyl-n-(thiophen-2-ylmethyl)propan-1-amine Chemical compound ClC1=CC=C(Cl)C(O[C@H](CCNCC=2SC=CC=2)C=2C=CC=CC=2)=C1 RIVMWJNNCKIJOQ-LJQANCHMSA-N 0.000 description 1
- QJOMJCYJMIWSPP-HXUWFJFHSA-N (3r)-3-(2,5-dichlorophenoxy)-n-[(5-methylfuran-2-yl)methyl]-3-phenylpropan-1-amine Chemical compound O1C(C)=CC=C1CNCC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=CC=C1Cl QJOMJCYJMIWSPP-HXUWFJFHSA-N 0.000 description 1
- MAVBXCBEBSAOBN-GFCCVEGCSA-N (3r)-3-(2,5-dichlorophenoxy)-n-methyl-3-thiophen-2-ylpropan-1-amine Chemical compound O([C@H](CCNC)C=1SC=CC=1)C1=CC(Cl)=CC=C1Cl MAVBXCBEBSAOBN-GFCCVEGCSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- BEVDEJZUPFTRCM-UHFFFAOYSA-N 1-(1,2-oxazol-3-yl)prop-2-en-1-one Chemical compound C=CC(=O)C=1C=CON=1 BEVDEJZUPFTRCM-UHFFFAOYSA-N 0.000 description 1
- WNCFOCZPFPWLPA-UHFFFAOYSA-N 1-thiophen-3-ylprop-2-en-1-one Chemical compound C=CC(=O)C=1C=CSC=1 WNCFOCZPFPWLPA-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- RANCECPPZPIPNO-UHFFFAOYSA-N 2,5-dichlorophenol Chemical compound OC1=CC(Cl)=CC=C1Cl RANCECPPZPIPNO-UHFFFAOYSA-N 0.000 description 1
- CHKKCGIKIGFBOG-UHFFFAOYSA-N 2-(3-amino-1-pyridin-3-ylpropoxy)-4-chloro-5-fluorobenzonitrile Chemical compound C=1C=CN=CC=1C(CCN)OC1=CC(Cl)=C(F)C=C1C#N CHKKCGIKIGFBOG-UHFFFAOYSA-N 0.000 description 1
- IKJONUGMJUMRJB-QGZVFWFLSA-N 2-[(1r)-3-(2-aminoethylamino)-1-phenylpropoxy]-4-chloro-5-fluorobenzonitrile Chemical compound O([C@H](CCNCCN)C=1C=CC=CC=1)C1=CC(Cl)=C(F)C=C1C#N IKJONUGMJUMRJB-QGZVFWFLSA-N 0.000 description 1
- QUJNCHROGUUCDL-OAHLLOKOSA-N 2-[(1r)-3-(2-aminoethylamino)-1-thiophen-3-ylpropoxy]-4-chloro-5-fluorobenzonitrile Chemical compound O([C@H](CCNCCN)C1=CSC=C1)C1=CC(Cl)=C(F)C=C1C#N QUJNCHROGUUCDL-OAHLLOKOSA-N 0.000 description 1
- BAKVXWJCQNRANW-OAHLLOKOSA-N 2-[(1r)-3-(tert-butylamino)-1-(1,2-oxazol-3-yl)propoxy]-4-chlorobenzonitrile Chemical compound O([C@H](CCNC(C)(C)C)C1=NOC=C1)C1=CC(Cl)=CC=C1C#N BAKVXWJCQNRANW-OAHLLOKOSA-N 0.000 description 1
- YCFJDGTTZCLOQI-GFCCVEGCSA-N 2-[(1r)-3-amino-1-(1,2-oxazol-3-yl)propoxy]-4-(trifluoromethyl)benzonitrile Chemical compound O([C@H](CCN)C1=NOC=C1)C1=CC(C(F)(F)F)=CC=C1C#N YCFJDGTTZCLOQI-GFCCVEGCSA-N 0.000 description 1
- VDTMUHOBBQUDBO-GFCCVEGCSA-N 2-[(1r)-3-amino-1-(1,2-oxazol-3-yl)propoxy]-4-chloro-5-fluorobenzonitrile Chemical compound O([C@H](CCN)C1=NOC=C1)C1=CC(Cl)=C(F)C=C1C#N VDTMUHOBBQUDBO-GFCCVEGCSA-N 0.000 description 1
- KBWORFWQMXSVEB-GFCCVEGCSA-N 2-[(1r)-3-amino-1-(1,2-oxazol-3-yl)propoxy]-4-chlorobenzonitrile Chemical compound O([C@H](CCN)C1=NOC=C1)C1=CC(Cl)=CC=C1C#N KBWORFWQMXSVEB-GFCCVEGCSA-N 0.000 description 1
- BDLWBJKHFVATGP-CYBMUJFWSA-N 2-[(1r)-3-amino-1-(1,2-oxazol-3-yl)propoxy]-5-fluoro-4-methylbenzonitrile Chemical compound C1=C(F)C(C)=CC(O[C@H](CCN)C2=NOC=C2)=C1C#N BDLWBJKHFVATGP-CYBMUJFWSA-N 0.000 description 1
- CWMAPWHHHSLCML-CSCOWPIISA-N 2-[(1r)-3-amino-1-(1,2-oxazol-3-yl)propoxy]-5-fluoro-4-methylbenzonitrile;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(C)=CC(O[C@H](CCN)C2=NOC=C2)=C1C#N CWMAPWHHHSLCML-CSCOWPIISA-N 0.000 description 1
- HHAUBWFVDJDTNA-LLVKDONJSA-N 2-[(1r)-3-amino-1-(1,3-thiazol-2-yl)propoxy]-4-chloro-5-fluorobenzonitrile Chemical compound O([C@H](CCN)C=1SC=CN=1)C1=CC(Cl)=C(F)C=C1C#N HHAUBWFVDJDTNA-LLVKDONJSA-N 0.000 description 1
- OQEWGPXWBMMTSU-RFVHGSKJSA-N 2-[(1r)-3-amino-1-(1,3-thiazol-2-yl)propoxy]-4-chloro-5-fluorobenzonitrile;hydrochloride Chemical compound Cl.O([C@H](CCN)C=1SC=CN=1)C1=CC(Cl)=C(F)C=C1C#N OQEWGPXWBMMTSU-RFVHGSKJSA-N 0.000 description 1
- RJPZNHMBLFJTLV-LLVKDONJSA-N 2-[(1r)-3-amino-1-(1,3-thiazol-2-yl)propoxy]-4-chlorobenzonitrile Chemical compound O([C@H](CCN)C=1SC=CN=1)C1=CC(Cl)=CC=C1C#N RJPZNHMBLFJTLV-LLVKDONJSA-N 0.000 description 1
- KLYYXFZIPFOYGL-CYBMUJFWSA-N 2-[(1r)-3-amino-1-(5-methyl-1,2-oxazol-3-yl)propoxy]-4-chloro-5-fluorobenzonitrile Chemical compound O1C(C)=CC([C@@H](CCN)OC=2C(=CC(F)=C(Cl)C=2)C#N)=N1 KLYYXFZIPFOYGL-CYBMUJFWSA-N 0.000 description 1
- FTOZEXQJADZUTJ-LLVKDONJSA-N 2-[(1r)-3-chloro-1-(2,5-dichlorophenoxy)propyl]thiophene Chemical compound O([C@H](CCCl)C=1SC=CC=1)C1=CC(Cl)=CC=C1Cl FTOZEXQJADZUTJ-LLVKDONJSA-N 0.000 description 1
- XNAWIGHQJLRRQG-UHFFFAOYSA-N 2-[3-amino-1-(1,2-oxazol-5-yl)propoxy]-4-chlorobenzonitrile Chemical compound C=1C=NOC=1C(CCN)OC1=CC(Cl)=CC=C1C#N XNAWIGHQJLRRQG-UHFFFAOYSA-N 0.000 description 1
- BTGIGRCIJOTYEE-UHFFFAOYSA-N 2-[3-amino-1-(1,3-oxazol-2-yl)propoxy]-4-chlorobenzonitrile Chemical compound N=1C=COC=1C(CCN)OC1=CC(Cl)=CC=C1C#N BTGIGRCIJOTYEE-UHFFFAOYSA-N 0.000 description 1
- OJVJWNHLCJDBOU-UHFFFAOYSA-N 2-[3-amino-1-(6-bromopyridin-3-yl)propoxy]-4-chlorobenzonitrile Chemical compound C=1C=C(Br)N=CC=1C(CCN)OC1=CC(Cl)=CC=C1C#N OJVJWNHLCJDBOU-UHFFFAOYSA-N 0.000 description 1
- SQYVUFDKECSCJO-UHFFFAOYSA-N 2-[3-amino-1-(6-methoxypyridin-2-yl)propoxy]-4-chloro-5-fluorobenzonitrile Chemical compound COC1=CC=CC(C(CCN)OC=2C(=CC(F)=C(Cl)C=2)C#N)=N1 SQYVUFDKECSCJO-UHFFFAOYSA-N 0.000 description 1
- TUVUAJSHBAXPTB-UHFFFAOYSA-N 2-[3-amino-1-(6-oxo-1h-pyridin-2-yl)propoxy]-4-chloro-5-fluorobenzonitrile Chemical compound C=1C=CC(=O)NC=1C(CCN)OC1=CC(Cl)=C(F)C=C1C#N TUVUAJSHBAXPTB-UHFFFAOYSA-N 0.000 description 1
- MSMLUJTUYBMOAH-CYBMUJFWSA-N 2-[[(3r)-3-(2,5-dichlorophenoxy)-3-thiophen-2-ylpropyl]amino]ethanol Chemical compound O([C@H](CCNCCO)C=1SC=CC=1)C1=CC(Cl)=CC=C1Cl MSMLUJTUYBMOAH-CYBMUJFWSA-N 0.000 description 1
- GSZTTZGTPCUMPI-UHFFFAOYSA-N 3-(2,5-dichlorophenoxy)-3-(1,3-oxazol-2-yl)propan-1-amine Chemical compound N=1C=COC=1C(CCN)OC1=CC(Cl)=CC=C1Cl GSZTTZGTPCUMPI-UHFFFAOYSA-N 0.000 description 1
- XKISXZUMKUNSEX-QGZVFWFLSA-N 3-[[(3r)-3-(2,5-dichlorophenoxy)-3-phenylpropyl]amino]propan-1-ol Chemical compound O([C@H](CCNCCCO)C=1C=CC=CC=1)C1=CC(Cl)=CC=C1Cl XKISXZUMKUNSEX-QGZVFWFLSA-N 0.000 description 1
- UVJSMYNJACGREF-UHFFFAOYSA-N 3-chloro-1-(1,2-oxazol-5-yl)propan-1-ol Chemical compound ClCCC(O)C1=CC=NO1 UVJSMYNJACGREF-UHFFFAOYSA-N 0.000 description 1
- XTMFISXDSXYCFX-UHFFFAOYSA-N 3-chloro-1-(1,2-oxazol-5-yl)propan-1-one Chemical compound ClCCC(=O)C1=CC=NO1 XTMFISXDSXYCFX-UHFFFAOYSA-N 0.000 description 1
- KAICFSLMBPZUME-UHFFFAOYSA-N 3-chloro-2-hydroxybenzonitrile Chemical compound OC1=C(Cl)C=CC=C1C#N KAICFSLMBPZUME-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- KAIVRQYFNYWFJG-MRXNPFEDSA-N 4-bromo-5-fluoro-2-[(1r)-1-(furan-3-yl)-3-(3-hydroxypropylamino)propoxy]benzonitrile Chemical compound O([C@H](CCNCCCO)C1=COC=C1)C1=CC(Br)=C(F)C=C1C#N KAIVRQYFNYWFJG-MRXNPFEDSA-N 0.000 description 1
- OZKPQUTYCWRVCS-GOSISDBHSA-N 4-bromo-5-fluoro-2-[(1r)-3-(3-hydroxypropylamino)-1-phenylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCCO)C=1C=CC=CC=1)C1=CC(Br)=C(F)C=C1C#N OZKPQUTYCWRVCS-GOSISDBHSA-N 0.000 description 1
- IJJYXVCGZIUAOZ-MRXNPFEDSA-N 4-bromo-5-fluoro-2-[(1r)-3-(3-hydroxypropylamino)-1-thiophen-3-ylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCCO)C1=CSC=C1)C1=CC(Br)=C(F)C=C1C#N IJJYXVCGZIUAOZ-MRXNPFEDSA-N 0.000 description 1
- HVIFIGDFMBLUGH-HXUWFJFHSA-N 4-chloro-2-[(1r)-3-(4-hydroxypiperidin-1-yl)-1-phenylpropoxy]benzonitrile Chemical compound C1CC(O)CCN1CC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=CC=C1C#N HVIFIGDFMBLUGH-HXUWFJFHSA-N 0.000 description 1
- POWMHQIVIVQPRF-GFCCVEGCSA-N 4-chloro-2-[(1r)-3-(methylamino)-1-(1,3-thiazol-2-yl)propoxy]benzonitrile Chemical compound O([C@H](CCNC)C=1SC=CN=1)C1=CC(Cl)=CC=C1C#N POWMHQIVIVQPRF-GFCCVEGCSA-N 0.000 description 1
- XFORHSSANNSJHD-PKLMIRHRSA-N 4-chloro-2-[(1r)-3-(methylamino)-1-phenylpropoxy]benzonitrile;hydrochloride Chemical compound Cl.O([C@H](CCNC)C=1C=CC=CC=1)C1=CC(Cl)=CC=C1C#N XFORHSSANNSJHD-PKLMIRHRSA-N 0.000 description 1
- MHBSSXASVYYPRN-RTBURBONSA-N 4-chloro-2-[(1r)-3-[(3r)-3-hydroxypyrrolidin-1-yl]-1-phenylpropoxy]benzonitrile Chemical compound C1[C@H](O)CCN1CC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=CC=C1C#N MHBSSXASVYYPRN-RTBURBONSA-N 0.000 description 1
- MHBSSXASVYYPRN-RBUKOAKNSA-N 4-chloro-2-[(1r)-3-[(3s)-3-hydroxypyrrolidin-1-yl]-1-phenylpropoxy]benzonitrile Chemical compound C1[C@@H](O)CCN1CC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=CC=C1C#N MHBSSXASVYYPRN-RBUKOAKNSA-N 0.000 description 1
- CDJGBWICHPFSIK-LJQANCHMSA-N 4-chloro-2-[(1r)-3-[2-(dimethylamino)ethylamino]-1-phenylpropoxy]-5-fluorobenzonitrile Chemical compound O([C@H](CCNCCN(C)C)C=1C=CC=CC=1)C1=CC(Cl)=C(F)C=C1C#N CDJGBWICHPFSIK-LJQANCHMSA-N 0.000 description 1
- HOZGPAFFOYJBCC-GOSISDBHSA-N 4-chloro-2-[(1r)-3-[2-hydroxyethyl(methyl)amino]-1-phenylpropoxy]benzonitrile Chemical compound O([C@H](CCN(CCO)C)C=1C=CC=CC=1)C1=CC(Cl)=CC=C1C#N HOZGPAFFOYJBCC-GOSISDBHSA-N 0.000 description 1
- VATYXLWXWFNTLY-UHFFFAOYSA-N 4-chloro-2-[3-(2-hydroxyethylamino)-1-(1,2-oxazol-5-yl)propoxy]benzonitrile Chemical compound C=1C=NOC=1C(CCNCCO)OC1=CC(Cl)=CC=C1C#N VATYXLWXWFNTLY-UHFFFAOYSA-N 0.000 description 1
- POWMHQIVIVQPRF-UHFFFAOYSA-N 4-chloro-2-[3-(methylamino)-1-(1,3-thiazol-2-yl)propoxy]benzonitrile Chemical compound N=1C=CSC=1C(CCNC)OC1=CC(Cl)=CC=C1C#N POWMHQIVIVQPRF-UHFFFAOYSA-N 0.000 description 1
- XFORHSSANNSJHD-UHFFFAOYSA-N 4-chloro-2-[3-(methylamino)-1-phenylpropoxy]benzonitrile;hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC(Cl)=CC=C1C#N XFORHSSANNSJHD-UHFFFAOYSA-N 0.000 description 1
- VZIUFIXJAFAQLA-QGZVFWFLSA-N 4-chloro-5-fluoro-2-[(1r)-1-phenyl-3-(3,3,3-trifluoropropylamino)propoxy]benzonitrile Chemical compound C1=C(Cl)C(F)=CC(C#N)=C1O[C@H](CCNCCC(F)(F)F)C1=CC=CC=C1 VZIUFIXJAFAQLA-QGZVFWFLSA-N 0.000 description 1
- JBSSGULETSXVMV-GOSISDBHSA-N 4-chloro-5-fluoro-2-[(1r)-3-(1h-imidazol-2-ylmethylamino)-1-phenylpropoxy]benzonitrile Chemical compound C1=C(Cl)C(F)=CC(C#N)=C1O[C@@H](C=1C=CC=CC=1)CCNCC1=NC=CN1 JBSSGULETSXVMV-GOSISDBHSA-N 0.000 description 1
- CTJAOABFWGKQNH-QGZVFWFLSA-N 4-chloro-5-fluoro-2-[(1r)-3-(2-fluoroethylamino)-1-phenylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCF)C=1C=CC=CC=1)C1=CC(Cl)=C(F)C=C1C#N CTJAOABFWGKQNH-QGZVFWFLSA-N 0.000 description 1
- AWYONSRYDJZBBU-QGZVFWFLSA-N 4-chloro-5-fluoro-2-[(1r)-3-(2-hydroxyethylamino)-1-phenylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCO)C=1C=CC=CC=1)C1=CC(Cl)=C(F)C=C1C#N AWYONSRYDJZBBU-QGZVFWFLSA-N 0.000 description 1
- MQQLJYDPZCVMMZ-OAHLLOKOSA-N 4-chloro-5-fluoro-2-[(1r)-3-(2-hydroxyethylamino)-1-thiophen-3-ylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCO)C1=CSC=C1)C1=CC(Cl)=C(F)C=C1C#N MQQLJYDPZCVMMZ-OAHLLOKOSA-N 0.000 description 1
- AKHMQXKPPJRSKF-HXUWFJFHSA-N 4-chloro-5-fluoro-2-[(1r)-3-(2-imidazol-1-ylethylamino)-1-phenylpropoxy]benzonitrile Chemical compound C1=C(Cl)C(F)=CC(C#N)=C1O[C@@H](C=1C=CC=CC=1)CCNCCN1C=NC=C1 AKHMQXKPPJRSKF-HXUWFJFHSA-N 0.000 description 1
- LKHRLFWJYNHYTH-OAQYLSRUSA-N 4-chloro-5-fluoro-2-[(1r)-3-(2-morpholin-4-ylethylamino)-1-phenylpropoxy]benzonitrile Chemical compound C1=C(Cl)C(F)=CC(C#N)=C1O[C@@H](C=1C=CC=CC=1)CCNCCN1CCOCC1 LKHRLFWJYNHYTH-OAQYLSRUSA-N 0.000 description 1
- UODJMFFMQMVWMA-GOSISDBHSA-N 4-chloro-5-fluoro-2-[(1r)-3-(3-hydroxypropylamino)-1-phenylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCCO)C=1C=CC=CC=1)C1=CC(Cl)=C(F)C=C1C#N UODJMFFMQMVWMA-GOSISDBHSA-N 0.000 description 1
- ALAGKEZIIHHISL-MRXNPFEDSA-N 4-chloro-5-fluoro-2-[(1r)-3-(3-hydroxypropylamino)-1-thiophen-3-ylpropoxy]benzonitrile Chemical compound O([C@H](CCNCCCO)C1=CSC=C1)C1=CC(Cl)=C(F)C=C1C#N ALAGKEZIIHHISL-MRXNPFEDSA-N 0.000 description 1
- IIFCPRVPECQNTQ-OAQYLSRUSA-N 4-chloro-5-fluoro-2-[(1r)-3-[(5-methylpyrazin-2-yl)methylamino]-1-phenylpropoxy]benzonitrile Chemical compound C1=NC(C)=CN=C1CNCC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=C(F)C=C1C#N IIFCPRVPECQNTQ-OAQYLSRUSA-N 0.000 description 1
- XIWMMMWGQGMKMI-HXUWFJFHSA-N 4-chloro-5-fluoro-2-[(1r)-3-[2-(1h-imidazol-5-yl)ethylamino]-1-phenylpropoxy]benzonitrile Chemical compound C1=C(Cl)C(F)=CC(C#N)=C1O[C@@H](C=1C=CC=CC=1)CCNCCC1=CNC=N1 XIWMMMWGQGMKMI-HXUWFJFHSA-N 0.000 description 1
- OFFYOTJFXPLHRN-UHFFFAOYSA-N 4-chloro-5-fluoro-2-[3-(methylamino)-1-pyridin-3-ylpropoxy]benzonitrile Chemical compound C=1C=CN=CC=1C(CCNC)OC1=CC(Cl)=C(F)C=C1C#N OFFYOTJFXPLHRN-UHFFFAOYSA-N 0.000 description 1
- DSWFQPBLICXPRE-UHFFFAOYSA-N 4-chloro-5-fluoro-2-[3-(methylamino)-1-pyrimidin-2-ylpropoxy]benzonitrile Chemical compound N=1C=CC=NC=1C(CCNC)OC1=CC(Cl)=C(F)C=C1C#N DSWFQPBLICXPRE-UHFFFAOYSA-N 0.000 description 1
- QMSDFAMCISQTPB-OAHLLOKOSA-N 5-fluoro-2-[(1r)-3-(2-hydroxyethylamino)-1-(1,2-oxazol-3-yl)propoxy]-4-methylbenzonitrile Chemical compound C1=C(F)C(C)=CC(O[C@H](CCNCCO)C2=NOC=C2)=C1C#N QMSDFAMCISQTPB-OAHLLOKOSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- IDMOZJVUCHENBC-HXUWFJFHSA-N [1-[(3r)-3-(2,5-dichlorophenoxy)-3-phenylpropyl]piperidin-4-yl]methanol Chemical compound C1CC(CO)CCN1CC[C@H](C=1C=CC=CC=1)OC1=CC(Cl)=CC=C1Cl IDMOZJVUCHENBC-HXUWFJFHSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GBSWRIGNSGNIPQ-RXMQYKEDSA-N diazonio-[(3r)-3-hydroxy-3-(1,3-oxazol-2-yl)propyl]azanide Chemical compound N#[N+][N-]CC[C@@H](O)C1=NC=CO1 GBSWRIGNSGNIPQ-RXMQYKEDSA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- NZHZMBJOIREICZ-UHFFFAOYSA-N tert-butyl N-[3-(5-chloro-2-cyanophenoxy)-3-(1,3-thiazol-2-yl)propyl]-N-methylcarbamate Chemical compound N=1C=CSC=1C(CCN(C)C(=O)OC(C)(C)C)OC1=CC(Cl)=CC=C1C#N NZHZMBJOIREICZ-UHFFFAOYSA-N 0.000 description 1
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0004153.3A GB0004153D0 (en) | 2000-02-23 | 2000-02-23 | Novel use |
| GB0004153.3 | 2000-02-23 | ||
| PCT/SE2001/000373 WO2001062704A1 (en) | 2000-02-23 | 2001-02-20 | Novel use of phenylheteroalkylamine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003523988A JP2003523988A (ja) | 2003-08-12 |
| JP2003523988A5 true JP2003523988A5 (OSRAM) | 2008-04-10 |
Family
ID=9886165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561714A Withdrawn JP2003523988A (ja) | 2000-02-23 | 2001-02-20 | フェニルヘテロアルキルアミン誘導体の新規なる使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6887871B2 (OSRAM) |
| EP (1) | EP1263711B1 (OSRAM) |
| JP (1) | JP2003523988A (OSRAM) |
| KR (1) | KR100706736B1 (OSRAM) |
| CN (1) | CN1235870C (OSRAM) |
| AT (1) | ATE284860T1 (OSRAM) |
| AU (1) | AU781141B2 (OSRAM) |
| BR (1) | BR0108613A (OSRAM) |
| CA (1) | CA2397234A1 (OSRAM) |
| CO (1) | CO5261625A1 (OSRAM) |
| DE (1) | DE60107820T2 (OSRAM) |
| GB (1) | GB0004153D0 (OSRAM) |
| IL (1) | IL150635A0 (OSRAM) |
| MX (1) | MXPA02008203A (OSRAM) |
| NO (1) | NO20024014L (OSRAM) |
| NZ (1) | NZ520107A (OSRAM) |
| WO (1) | WO2001062704A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004152D0 (en) | 2000-02-23 | 2000-04-12 | Astrazeneca Uk Ltd | Novel compounds |
| AR035700A1 (es) * | 2001-05-08 | 2004-06-23 | Astrazeneca Ab | Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados |
| BR0211533A (pt) * | 2001-07-31 | 2004-07-13 | Upjohn Co | Tratamento de dor crÈnica com 3-heterociclil- e 3-cicloalquil-3-ariloxipropanaminas |
| EP1411912A1 (en) * | 2001-07-31 | 2004-04-28 | PHARMACIA & UPJOHN COMPANY | Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines |
| SE0102640D0 (sv) | 2001-07-31 | 2001-07-31 | Astrazeneca Ab | Novel compounds |
| PE20030701A1 (es) | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| SE0202280D0 (sv) | 2002-07-19 | 2002-07-19 | Astrazeneca Ab | Novel compounds |
| SE0202279D0 (sv) * | 2002-07-19 | 2002-07-19 | Astrazeneca Ab | Novel comppounds |
| SE0203304D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Coumpounds |
| KR101350071B1 (ko) * | 2006-01-13 | 2014-01-14 | 다우 아그로사이언시즈 엘엘씨 | 6-(다-치환 아릴)-4-아미노피콜리네이트 및 그의제초제로서의 용도 |
| ITMI20061987A1 (it) * | 2006-10-16 | 2008-04-17 | Archimica Srl | Processo per la sintesi di arilossipropilammine ed eteroarilossipropilammine. |
| PT2215092E (pt) | 2007-10-19 | 2012-04-10 | Boehringer Ingelheim Int | Piperidino-di-hidrotienopirimidinas substituídas |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| PL2513093T3 (pl) | 2009-12-17 | 2015-03-31 | Centrexion Therapeutics Corp | Nowi antagoniści receptora CCR2 i ich zastosowanie |
| US20130143905A1 (en) | 2009-12-17 | 2013-06-06 | Boehringer Ingelheim International Gmbh | Novel antagonists for ccr2 and uses thereof |
| BR112012018865A2 (pt) | 2010-01-29 | 2016-04-12 | Boehringer Ingelheim Int | naftiridinas substituídas e seu uso como inibidores de quinase syk |
| WO2011141477A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP2013526507A (ja) | 2010-05-12 | 2013-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用 |
| JP5647339B2 (ja) | 2010-05-17 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２アンタゴニスト及びこれらの使用 |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| JP5721242B2 (ja) | 2010-06-01 | 2015-05-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２アンタゴニスト |
| EP2593419A1 (en) | 2010-07-15 | 2013-05-22 | Albemarle Corporation | Processes for producing 4-bromo-2-methoxybenzaldehyde |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| WO2012171863A1 (en) | 2011-06-16 | 2012-12-20 | Boehringer Ingelheim International Gmbh | New selective ccr2 antagonists |
| AR086992A1 (es) | 2011-06-20 | 2014-02-05 | Bayer Ip Gmbh | Tienilpiri(mi)dinilpirazoles |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| JP5860960B2 (ja) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キノリン類及び医薬としてのそれらの使用 |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
| WO2015140051A1 (en) | 2014-03-19 | 2015-09-24 | Boehringer Ingelheim International Gmbh | Heteroaryl sik inhibitors |
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| CN118340754B (zh) * | 2024-04-15 | 2025-03-11 | 源道医药(苏州)有限公司 | 治疗心衰及其相关疾病的化合物和应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB765849A (en) | 1953-09-21 | 1957-01-16 | Univ Leeds | Improvements in or relating to new aminoalkyl phenyl ethers |
| GB922600A (en) | 1960-05-06 | 1963-04-03 | Crookes Lab Ltd | Ortho-tertiary-butyl phenolethers |
| US3205136A (en) | 1962-12-24 | 1965-09-07 | Smith Kline French Lab | Antidepressant phenyloxyalkylamines |
| JPS52941B1 (OSRAM) | 1969-12-09 | 1977-01-11 | ||
| JPS5144934B1 (OSRAM) | 1969-12-09 | 1976-12-01 | ||
| US4314081A (en) | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
| JPS52941A (en) * | 1975-06-24 | 1977-01-06 | Hitachi Chem Co Ltd | Polyurethane insulating coating composition |
| FR2432500A1 (fr) * | 1978-02-24 | 1980-02-29 | Roussel Uclaf | Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments |
| GB2060621A (en) | 1979-09-14 | 1981-05-07 | Wyeth John & Brother Ltd | 3-Aryl-3-aryloxypropylamines |
| GB2060622B (en) | 1979-09-14 | 1983-05-25 | Wyeth John & Brother Ltd | 3-aryl-3-aryloxyalkylamines |
| GB2060620B (en) | 1979-09-14 | 1983-05-25 | Wyeth John & Brother Ltd | 3-aryl-3-aryloxypropylamines |
| DE3138550A1 (de) | 1981-09-28 | 1983-04-07 | Boehringer Ingelheim KG, 6507 Ingelheim | Substituierte 2-phenyl-2-(pyridyloxy)-ethylamine und isostere verbindungen, verfahren zu ihrer herstellung und verwendung |
| KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
| DK630987D0 (da) | 1987-12-01 | 1987-12-01 | Ferrosan As | Aryloxyphenylpropylaminer, deres fremstilling og anvendelse |
| US4902710A (en) | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
| DK258389D0 (da) | 1989-05-26 | 1989-05-26 | Ferrosan As | Aryloxyphenylpropylaminer, deres fremstilling og anvendelse |
| US5320825A (en) | 1991-05-01 | 1994-06-14 | Trustees Of The University Of Pennsylvania | Serotonin reuptake inhibitors for S.P.E.C.T. imaging |
| FR2676054B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| EP0571685A1 (en) * | 1992-05-27 | 1993-12-01 | Novo Nordisk A/S | Aryloxyheteroarylpropylamines, their preparation and use |
| EP0576766A1 (en) | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
| EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
| DK0707007T3 (da) | 1994-10-14 | 2002-03-18 | Merck Patent Gmbh | Amino(thio)etherderivater som CNS-aktive midler |
| HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| HN1998000125A (es) | 1997-08-28 | 1999-02-09 | Pfizer Prod Inc | 2-aminopiridinas con sustituyentes alcoxi ramificados |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
| CA2319781A1 (en) | 1998-02-02 | 1999-08-05 | Liping Wang | Cyclic amine modulators of chemokine receptor activity |
| HUP0102236A3 (en) | 1998-06-03 | 2003-01-28 | Pfizer Prod Inc | 2-aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors and pharmaceutical compositions containing them and their use |
| PL346860A1 (en) * | 1998-09-08 | 2002-03-11 | Monsanto Co | Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors |
| SE9803773D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Pharma Prod | Compounds |
| KR20010108394A (ko) | 1999-03-26 | 2001-12-07 | 다비드 에 질레스 | 신규 화합물 |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| AU2002215928A1 (en) | 2000-10-09 | 2002-04-22 | Novartis Pharma Gmbh | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists |
| JP4716655B2 (ja) | 2001-11-21 | 2011-07-06 | ユニバーシティ・オブ・オーフース | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
-
2000
- 2000-02-23 GB GBGB0004153.3A patent/GB0004153D0/en active Pending
-
2001
- 2001-02-20 JP JP2001561714A patent/JP2003523988A/ja not_active Withdrawn
- 2001-02-20 AU AU34315/01A patent/AU781141B2/en not_active Ceased
- 2001-02-20 CN CNB018054897A patent/CN1235870C/zh not_active Expired - Fee Related
- 2001-02-20 MX MXPA02008203A patent/MXPA02008203A/es active IP Right Grant
- 2001-02-20 CO CO01013437A patent/CO5261625A1/es not_active Application Discontinuation
- 2001-02-20 AT AT01906492T patent/ATE284860T1/de not_active IP Right Cessation
- 2001-02-20 US US10/204,742 patent/US6887871B2/en not_active Expired - Fee Related
- 2001-02-20 IL IL15063501A patent/IL150635A0/xx unknown
- 2001-02-20 NZ NZ520107A patent/NZ520107A/en not_active Application Discontinuation
- 2001-02-20 KR KR1020027010975A patent/KR100706736B1/ko not_active Expired - Fee Related
- 2001-02-20 DE DE60107820T patent/DE60107820T2/de not_active Expired - Fee Related
- 2001-02-20 CA CA002397234A patent/CA2397234A1/en not_active Abandoned
- 2001-02-20 BR BR0108613-8A patent/BR0108613A/pt not_active IP Right Cessation
- 2001-02-20 WO PCT/SE2001/000373 patent/WO2001062704A1/en not_active Ceased
- 2001-02-20 EP EP01906492A patent/EP1263711B1/en not_active Expired - Lifetime
-
2002
- 2002-08-22 NO NO20024014A patent/NO20024014L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003523988A5 (OSRAM) | ||
| KR100706736B1 (ko) | 페닐헤테로알킬아민 유도체의 신규 용도 | |
| US7687664B2 (en) | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | |
| WO2013025733A1 (en) | Lysophosphatidic acid receptor antagonists | |
| EP1452521A1 (en) | Cyclic compound and ppar agonist | |
| CN101663281A (zh) | 抑制β-分泌酶的氨基-5-[4-(二氟甲氧基)苯基]-5-苯基咪唑啉酮化合物 | |
| OA12631A (fr) | Amides d'acide anthranilique avec une chaîne latérale hétéroarylsulfonyle, procédé our leur préparation, leur utilisation comme médeicament ou comme agent de diagnostic et préparations pharmaceutiquescontenant lesdits composés. | |
| JP2010533645A (ja) | 脂肪酸アミドヒドロラーゼの三環系阻害剤 | |
| JP2010533645A5 (OSRAM) | ||
| JP7751731B2 (ja) | グルコキナーゼ活性化剤としてのピロリドン誘導体のプロドラッグ | |
| JP2022521081A (ja) | Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体 | |
| CN115137726B (zh) | 作为缓激肽b1受体拮抗剂的羧酸芳族酰胺 | |
| CN102304104B (zh) | 一类trpv1拮抗剂、其制备方法及其医疗用途 | |
| JP2008512438A (ja) | 療法用ジフェニルエーテル系リガンド | |
| FR2909090A1 (fr) | Derives de 2,5-dihydro-3h-pyrazolo[4,3-c]pyridazin-3-one substitues,leur preparation et leur application en therapeutique. | |
| ES2328467T3 (es) | Derivados heterociclicos de 5 miembros, su preparacion y su aplicacion como medicamentos. | |
| JP2003523992A5 (OSRAM) | ||
| CN104039151A (zh) | 治疗中枢神经系统中小神经胶质细胞介导的神经元缺失的组织蛋白酶抑制剂 | |
| EP2912015A1 (fr) | Inhibiteurs mixtes de l'aminopeptidase n et de la néprilysine | |
| KR100721087B1 (ko) | 페닐헤테로알킬아민 유도체의 신규 용도 | |
| RU2752088C1 (ru) | Композиции для лечения гипертензии и/или фиброза | |
| HK40074980A (en) | Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor | |
| CN120192310A (zh) | 作为ripk1抑制剂的苯并氧氮杂卓化合物 | |
| HK40074980B (zh) | 作为缓激肽 b1 受体拮抗剂的羧酸芳族酰胺 | |
| CN117658885A (zh) | 苄氧芳基类化合物及其制备方法、药物组合物和用途 |